Cytosorbents Corp (CTSO) on Focus After Raising In Today’s Session

September 17, 2017 - By Peter Erickson

Investors sentiment decreased to 1.25 in Q4 2016. Its down 0.53, from 1.78 in 2016Q3. It fall, as 4 investors sold Cytosorbents Corp shares while 8 reduced holdings. 7 funds opened positions while 8 raised stakes. 1.20 million shares or 2.14% less from 1.23 million shares in 2016Q3 were reported.
Morgan Stanley reported 1,153 shares. Geode Cap Limited Liability Corp owns 126,277 shares. Wells Fargo Company Mn accumulated 0% or 1,500 shares. Blackrock has 400 shares for 0% of their portfolio. Northern Tru Corporation accumulated 24,574 shares. Manufacturers Life The holds 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO) for 2,164 shares. 65,442 were reported by Raymond James & Associate. Tower Rech Ltd Limited Liability Company (Trc) holds 0% or 1,440 shares. Glenmede Trust Company Na holds 19,008 shares. Millennium Ltd Llc has invested 0% of its portfolio in Cytosorbents Corp (NASDAQ:CTSO). 64,489 are owned by Blackrock Fund Advsrs. Barclays Pcl reported 50 shares. Vanguard Group has 0% invested in Cytosorbents Corp (NASDAQ:CTSO). Fortaleza Asset Mngmt Inc reported 24,875 shares. 11,347 are held by Susquehanna Llp.

Since May 15, 2017, it had 7 insider purchases, and 0 selling transactions for $80,608 activity. Shares for $10,000 were bought by Capponi Vincent. BLOCH KATHLEEN P. bought $4,341 worth of stock. Another trade for 1,500 shares valued at $6,180 was bought by BATOR MICHAEL G.. Mortensen Eric R. bought $10,100 worth of stock. Another trade for 6,300 shares valued at $25,200 was made by Chan Phillip P. on Monday, June 5.

The stock of Cytosorbents Corp (NASDAQ:CTSO) is a huge mover today! The stock increased 3.77% or $0.2 on September 15, reaching $5.5. About 170,282 shares traded or 15.08% up from the average. Cytosorbents Corp (NASDAQ:CTSO) has declined 4.26% since September 17, 2016 and is downtrending. It has underperformed by 20.96% the S&P500.
The move comes after 6 months positive chart setup for the $154.74 million company. It was reported on Sep, 17 by Barchart.com. We have $5.67 PT which if reached, will make NASDAQ:CTSO worth $4.64M more.

Wall Street await Cytosorbents Corp (NASDAQ:CTSO) to release earnings on November, 6. Analysts forecast EPS of $-0.09, up exactly $0.02 or 18.18 % from 2014’s $-0.11 EPS. After posting $-0.04 EPS for the previous quarter, Cytosorbents Corp’s analysts now forecast 125.00 % negative EPS growth.

Cytosorbents Corp (NASDAQ:CTSO) Ratings Coverage

Among 6 analysts covering CytoSorbents (NASDAQ:CTSO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CytoSorbents had 10 analyst reports since October 29, 2015 according to SRatingsIntel. B. Riley & Co initiated Cytosorbents Corp (NASDAQ:CTSO) on Friday, October 7 with “Buy” rating. Aegis Capital maintained Cytosorbents Corp (NASDAQ:CTSO) on Tuesday, May 30 with “Buy” rating. On Tuesday, May 24 the stock rating was initiated by Maxim Group with “Buy”. The firm earned “Buy” rating on Wednesday, October 26 by Aegis Capital. The rating was maintained by Maxim Group with “Buy” on Tuesday, August 8. The stock of Cytosorbents Corp (NASDAQ:CTSO) earned “Buy” rating by Maxim Group on Wednesday, July 5. WBB Securities upgraded the stock to “Buy” rating in Thursday, October 29 report. Maxim Group maintained Cytosorbents Corp (NASDAQ:CTSO) on Monday, July 17 with “Buy” rating.

More notable recent Cytosorbents Corp (NASDAQ:CTSO) news were published by: Seekingalpha.com which released: “Cytosorbents’ (CTSO) CEO Phillip Chan on Q1 2017 Results – Earnings Call …” on May 09, 2017, also Prnewswire.com with their article: “CytoSorbents Announces Pricing of Follow-On Offering” published on March 31, 2017, Seekingalpha.com published: “CytoSorbents’ (CTSO) CEO Dr. Phillip Chan on Q2 2017 Results – Earnings Call …” on August 08, 2017. More interesting news about Cytosorbents Corp (NASDAQ:CTSO) were released by: Prnewswire.com and their article: “CytoSorbents to Report Q2 2017 Operating and Financial Results” published on August 01, 2017 as well as Prnewswire.com‘s news article titled: “CytoSorbents Awarded $719000 Grant To Acutely Stabilize Severe Burn Patients” with publication date: August 14, 2017.

CytoSorbents Corporation is a critical care focused immunotherapy company. The company has market cap of $154.74 million. The Firm is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. It currently has negative earnings. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.